Accessing Innovative Orphan Therapies in China: Local Advancements
These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
Fostering Medical Innovation: How China's Social and Commercial Insurance Can Work Together
A healthy innovation ecosystem for medicines in China requires effective integration between basic and commercial health insurance. Success hinges on stakeholders operating within China's social security framework and focusing first on tackling the low-hanging fruit.
Impacts of Provincial Central Pooling of Basic Medical Insurance on China's Healthcare Ecosystem
Increasing the risk pooling level is essential for reducing regional disparities and improving the efficiency of BMI funds. This change will deeply affect the supply and demand sides of China's healthcare ecosystem.
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations
These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare
These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China
In this inaugural annual NRDL+ debrief, we comprehensively examined pivotal developments and trends across basic medical insurance schemes, the commercial
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions
During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
